% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kluge:1027018,
author = {Kluge, Annika and Schaeffer, Eva and Bunk, Josina and
Sommerauer, Michael and Röttgen, Sinah and Schulte, Claudia
and Roeben, Benjamin and von Thaler, Anna-Katharina and
Welzel, Julius and Lucius, Ralph and Heinzel, Sebastian and
Xiang, Wei and Eschweiler, Gerhard W. and Maetzler, Walter
and Suenkel, Ulrike and Berg, Daniela},
title = {{D}etecting {M}isfolded α‐{S}ynuclein in {B}lood {Y}ears
before the {D}iagnosis of {P}arkinson's {D}isease},
journal = {Movement disorders},
volume = {39},
number = {8},
issn = {0885-3185},
address = {New York, NY},
publisher = {Wiley},
reportid = {FZJ-2024-03584},
pages = {1289-1299},
year = {2024},
abstract = {BackgroundIdentifying individuals with Parkinson's disease
(PD) already in the prodromal phase of the disease has
become a priority objective for opening a window for early
disease-modifying therapies.ObjectiveThe aim was to evaluate
a blood-based α-synuclein seed amplification assay (α-syn
SAA) as a novel biomarker for diagnosing PD in the prodromal
phase.MethodsIn the TREND study (University of Tuebingen)
biennial blood samples of n = 1201 individuals
with/without increased risk for PD were taken prospectively
over 4 to 10 years. We retrospectively analyzed blood
samples of 12 participants later diagnosed with PD during
the study to detect and amplify pathological α-syn
conformers derived from neuronal extracellular vesicles
using (1) immunoblot analyses with an antibody against these
conformers and (2) an α-syn-SAA. Additionally, blood
samples of n = 13 healthy individuals from the TREND
cohort and n = 20 individuals with isolated rapid eye
movement sleep behavior disorder (iRBD) from the University
Hospital Cologne were analyzed.ResultsAll individuals with
PD showed positive immunoblots and a positive α-syn SAA at
the time of diagnosis. Moreover, all PD patients showed a
positive α-syn SAA 1 to 10 years before clinical
diagnosis. In the iRBD cohort, $30\%$ showed a positive
α-syn SAA. All healthy controls had a negative
SAA.ConclusionsWe here demonstrate the possibility to detect
and amplify pathological α-syn conformers in peripheral
blood up to 10 years before the clinical diagnosis of PD
in individuals with and without iRBD. The findings of this
study indicate that this blood-based α-syn SAA assay has
the potential to serve as a diagnostic biomarker for
prodromal PD. © 2024 The Authors. Movement Disorders
published by Wiley Periodicals LLC on behalf of
International Parkinson and Movement Disorder Society.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
pid = {G:(DE-HGF)POF4-5252},
typ = {PUB:(DE-HGF)16},
pubmed = {38651526},
UT = {WOS:001206343800001},
doi = {10.1002/mds.29766},
url = {https://juser.fz-juelich.de/record/1027018},
}